NEUMORA THERAPEUTICS, INC. Total Liabilities and Equity
NEUMORA THERAPEUTICS, INC. (NMRA) had Total Liabilities and Equity of $125.25 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-14
- 2026-06-30: Liabilities and Equity $125.25M.
- 2026-03-31: Liabilities and Equity $153.88M.
- 2025-12-31: Liabilities and Equity $191.05M.
- 2025-09-30: Liabilities and Equity $177.83M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $125.25M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $153.88M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $191.05M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $177.83M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $223.82M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $256.75M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $316.97M 10-K · filed 2026-03-30 |
| 2024-09-30 | $352.54M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $404.47M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $450.21M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $496.19M 10-K · filed 2025-03-03 |
| 2023-09-30 | $544.75M 10-Q · filed 2023-11-01 |
| 2022-12-31 | $426.23M 10-K · filed 2024-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |